Pfizer Acquires Warner-Lambert in a Hostile Takeover
In 1996 Pfizer and Warner Lambert (Warner) agreed to co-market worldwide the cholesterol-lowering drug Lipitor, which
had been developed by Warner. The combined marketing effort was extremely successful with combined 1999 sales reaching
$3.5 billion, a 60% increase over 1998. Before entering into the marketing agreement, Pfizer had entered into a
confidentiality agreement with Warner that contained a standstill clause that, among other things, prohibited Pfizer from
making a merger proposal unless invited to do so by Warner or until a third party made such a proposal.
In late 1998, Pfizer became aware of numerous rumors of a possible merger between Warner and some unknown entity.
The public announcement of the agreement to merge between Warner and AHP released Pfizer from the standstill
agreement. Tinged with frustration and impatience at what Pfizer saw as stalling tactics, Steere outlined in the letter the
primary reasons why the proposed combination of the two companies made sense to Warner’s shareholders. In addition to a
substantial premium over Warner’s current share price, Pfizer argued that combining the companies would result in a
veritable global powerhouse in the pharmaceutical industry. Furthermore, the firm’s product lines are highly complementary,
including Warner’s over-the-counter drug presence and substantial pipeline of new drugs and Pfizer’s powerful global
In addition to the letter from Steere to de Vink, on November 4, 1999, Pfizer announced that it had commenced a legal
action in the Delaware Court of Chancery against Warner, Warner’s directors, and AHP. The action sought to enjoin the
approximately $2 billion termination fee and the stock option granted by Warner-Lambert to AHP to acquire 14.9% of
On November 5, 1999, Warner explicitly rejected Pfizer’s proposal in a press release and reaffirmed its commitment to its
announced business combination with AHP. On November 9, 1999, de Vink sent a letter to the Pfizer board in which he
expressed Warner’s disappointment at what he perceived to be Pfizer’s efforts to take over Warner as well as Pfizer’s lawsuit
against the firm. In the letter, he stated Warner-Lambert’s belief that the litigation was not in the best interest of either
company’s stockholders, especially in light of their co-promotion of Lipitor, and it was causing uncertainty in the financial
markets. Not only did Warner reject the Pfizer bid, but it also threatened to cancel the companies’ partnership to market
Lipitor.
Pfizer responded by exploiting a weakness in the Warner Lambert takeover defenses by utilizing a consent solicitation
process that allows shareholders to change the board without waiting months for a shareholders’ meeting. Pfizer also
challenged in court two provisions in the contract with AHP on the grounds that they were not in the best interests of the
Warner Lambert shareholders because they would discourage other bidders. Pfizer’s offers for Warner Lambert were